{"url_path":"/sec/aura/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-11","source_url":"https://www.sec.gov/Archives/edgar/data/1501796/0001193125-26-216808-index.html","accession_number":"0001193125-26-216808","cik":"0001501796","ticker":"AURA","issuer_name":"Aura Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1501796/0001193125-26-216808-index.html","primary_entity_key":"0001501796","primary_entity_name":"Aura Biosciences, Inc."},"word_count":109,"has_tables":true,"body_markdown":"Item 1. Legal Proceedings.\n\nFrom time to time, we may become subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of March 31, 2026, we do not believe we are party to any claim or litigation, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors."}